Fellow

Andrew Hopkins, CEO of Exscientia plc, has pioneered the application of machine learning and artificial intelligence to drug design and its practical and commercial applications. Exscientia is the most successful healthcare spin-out from UK academia and is the fastest growing, and now second largest biotech company in Britain. It is now a global company with over 450 employees across the UK, USA, Austria, and Japan. Under his leadership, the company invented the first three drug candidates designed by AI ever to enter human clinical trials, with another five novel molecules in IND-enabling studies, and over 25 projects in the pipeline. He conceived the concepts of “the druggable genome”, “ligand efficiency” and “chemical beauty” which influenced the pharmaceutical industry’s approach to target selection and drug design over the past two decades.